Could turmeric help your memory? new study tests it

NCT ID NCT04705220

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested whether a special turmeric supplement (MERIVA®) could improve memory and thinking in older adults with metabolic syndrome. 85 people took either the supplement or a placebo for 6 months. Researchers measured changes in cognitive tests to see if turmeric helped protect against age-related mental decline.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
turmeric supplement (MERIVA®)
What this could lead to
If it works, this could point toward a simple dietary supplement to help protect memory and thinking in older adults with metabolic syndrome.
What could go wrong
This is a small, completed trial with 85 people. The results may not apply to everyone, and the improvement seen might be modest or not better than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

85 people

The number who actually took part.

Started

Apr 2022

Finished

Dec 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female subjects. * Subjects aged ≥ 60 years. * Subjects with Metabolic Syndrome diagnosed according to standard criteria: 1. Presence of abdominal obesity (waist circumference\> 94 cm for males and\> 80 cm for females). In addition, at least two of the following alterations: 2. Fasting blood glucose ≥ 100 mg / dl. 3. Triglycerides ≥ 150 mg / dl. 4. HDL cholesterol \<40 mg / dl for males, \<50 mg / dl for females. 5. Arterial hypertension (≥ 135/85 mmHg). * Subjects who understand the nature of the study and provide their informed consent to participate. * Subjects willing and able to participate in the visits and in the procedures foreseen by the study protocol. Exclusion Criteria: * Subjects with dementia with MMSE \<24 test and on therapy with cholinesterase inhibitors or memantine\*. * Subjects with serious concomitant internal medical conditions or with neurological pathologies capable of causing cognitive dysfunction. * Subjects with hepato-biliary disorders, including bile duct obstruction, cholangitis, gallstones. * Subjects addicted to alcohol or drugs, or treated with psychotropic drugs at the time of enrollment. * Subjects with known or suspected allergy or hypersensitivity to turmeric or other components of the experimental / placebo product. * Subjects with Mild Cognitive Impairment (MCI) and in experimental therapy with Alzheimer's disease drugs. * Subjects who are participating or have participated in other clinical studies within 30 days before enrollment. * Subjects unable to sign the Informed Consent to Participation. * In case of conversion to dementia the Subjects will be kept in the study, will be subjected to the most appropriate therapies provided for the dementia pathology but will not enter the subsequent statistical evaluations.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metabolic syndrome are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • S.C. di Endocrinologia e Diabetologia, Policlinico Universitario "Agostino Gemelli"

    Roma, 00168, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.